Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+

NCT02128061 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Lenalidomide
DRUG: Rituximab

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]